See more : Impact Minerals Limited (IPT.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Aeterna Zentaris Inc. (AEZS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aeterna Zentaris Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Global Ship Lease, Inc. 8.00% S (GSLD) Income Statement Analysis – Financial Results
- NIO Inc. (N3IA.F) Income Statement Analysis – Financial Results
- Corporación Acciona Energías Renovables, S.A. (ANE.MC) Income Statement Analysis – Financial Results
- Rama Steel Tubes Limited (RAMASTEEL.BO) Income Statement Analysis – Financial Results
- Fox-Wizel Ltd. (FXWZF) Income Statement Analysis – Financial Results
Aeterna Zentaris Inc. (AEZS)
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.58M | 5.64M | 5.26M | 3.65M | 532.00K | 26.88M | 923.00K | 911.00K | 545.00K | 11.00K | 6.18M | 33.67M | 36.05M | 27.70M | 63.24M | 38.48M | 42.07M | 41.39M | 247.39M | 194.03M | 128.33M | 64.28M | 27.50M | 5.61M | 4.25M | 2.79M | 4.47M | 2.04M |
| Cost of Revenue | 398.17K | 157.00K | 90.00K | 2.32M | 410.00K | 2.10M | 0.00 | 0.00 | 249.59K | 0.00 | 51.00K | 26.82M | 27.56M | 18.70M | 16.50M | 19.28M | 12.93M | 11.75M | 156.37M | 111.91M | 75.61M | 49.19M | 18.81M | 749.33K | 705.76K | 1.49M | 1.96M | 1.75M |
| Gross Profit | 4.18M | 5.48M | 5.17M | 1.34M | 122.00K | 24.78M | 923.00K | 911.00K | 295.41K | 11.00K | 6.12M | 6.85M | 8.49M | 9.00M | 46.74M | 19.20M | 29.14M | 29.65M | 91.02M | 82.11M | 52.72M | 15.09M | 8.69M | 4.86M | 3.55M | 1.30M | 2.52M | 291.89K |
| Gross Profit Ratio | 91.31% | 97.22% | 98.29% | 36.56% | 22.93% | 92.17% | 100.00% | 100.00% | 54.20% | 100.00% | 99.17% | 20.33% | 23.56% | 32.50% | 73.91% | 49.90% | 69.26% | 71.62% | 36.79% | 42.32% | 41.08% | 23.48% | 31.58% | 86.63% | 83.40% | 46.51% | 56.25% | 14.29% |
| Research & Development | 13.81M | 12.51M | 6.57M | 1.51M | 1.84M | 2.93M | 10.70M | 16.50M | 17.23M | 23.72M | 21.28M | 20.60M | 24.52M | 19.86M | 44.22M | 57.11M | 37.19M | 27.09M | 26.97M | 25.26M | 34.03M | 15.33M | 14.59M | 10.62M | 8.40M | 6.04M | 4.26M | 3.28M |
| General & Administrative | 8.72M | 8.23M | 5.92M | 4.76M | 6.62M | 8.89M | 8.20M | 7.15M | 11.31M | 9.84M | 8.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -12.11K | 8.23M | 1.35M | 1.13M | 1.21M | 3.11M | 5.10M | 6.75M | 6.89M | 13.69M | 12.32M | 13.25M | 0.00 | 11.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.71M | 8.23M | 7.27M | 5.89M | 7.83M | 12.00M | 13.29M | 13.89M | 18.20M | 13.69M | 12.32M | 13.25M | 16.17M | 11.88M | 16.04M | 17.33M | 20.40M | 17.24M | 42.04M | 35.10M | 22.44M | 11.29M | 4.08M | 1.72M | 1.42M | 0.00 | 0.00 | 0.00 |
| Other Expenses | -13.00K | 8.51M | 90.00K | 146.34K | 1.11M | -1.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.81M | 10.84M | 7.15M | 6.30M | 9.43M | 26.61M | 7.47M | 7.26M | 1.54M | 1.16M | 969.37K | 709.21K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 22.52M | 20.74M | 13.84M | 7.40M | 9.67M | 14.94M | 24.00M | 30.39M | 35.43M | 37.41M | 33.60M | 33.85M | 40.69M | 34.23M | 70.69M | 81.58M | 63.89M | 53.75M | 95.61M | 67.83M | 63.73M | 28.16M | 19.84M | 13.30M | 10.53M | 5.33M | 3.56M | 2.26M |
| Cost & Expenses | 22.92M | 20.89M | 13.93M | 9.72M | 10.08M | 17.04M | 24.00M | 30.39M | 35.43M | 37.41M | 33.65M | 60.67M | 68.25M | 52.93M | 87.20M | 100.86M | 76.82M | 65.50M | 251.98M | 179.75M | 139.34M | 77.35M | 38.65M | 14.05M | 11.24M | 6.82M | 5.52M | 4.01M |
| Interest Income | 1.13M | 4.00K | 7.00K | 4.00K | 593.00K | 278.00K | 75.00K | 150.00K | 143.00K | 168.00K | 185.00K | 6.97M | 6.24M | 207.00K | 349.00K | 0.00 | 0.00 | 1.45M | 1.60M | 0.00 | 1.65M | 0.00 | 0.00 | 2.41M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 128.13K | 3.00K | 21.00K | 774.88K | 593.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.51M | 382.00K | 8.00K | 26.00K | 5.00K | 0.00 | 0.00 | 1.45M | 9.79M | 0.00 | 3.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 172.10K | 129.65K | 143.72K | 244.26K | 322.32K | 56.94K | 142.96K | 192.65K | 341.00K | 878.00K | 949.00K | 1.32M | 2.88M | 2.50M | 10.84M | 1.67M | 5.57M | 9.43M | 7.60M | 7.47M | 7.27M | 1.54M | 1.16M | 969.37K | 709.21K | 324.95K | 139.76K | 145.94K |
| EBITDA | -2.89M | -7.65M | -8.53M | -7.91M | -10.24M | 9.84M | -23.81M | -28.79M | -34.54M | -36.52M | -24.41M | -27.00M | -32.19M | -22.52M | -12.77M | -58.22M | -62.38M | -15.39M | -15.73M | 23.04M | -2.49M | -11.80M | -16.41M | -15.10M | -9.66M | -5.20M | -2.17M | -3.94M |
| EBITDA Ratio | -396.60% | -135.59% | -162.09% | -216.57% | -1,734.77% | 33.41% | -2,784.83% | -3,684.19% | -6,338.17% | -331,972.73% | -429.59% | -55.58% | -64.01% | -81.31% | -20.19% | -151.31% | -65.11% | -37.17% | -6.36% | 11.88% | -1.94% | -18.35% | -59.68% | -269.40% | -227.32% | -186.05% | -48.44% | -192.86% |
| Operating Income | -18.34M | -15.25M | -8.67M | -6.06M | -9.54M | 9.84M | -23.07M | -29.48M | -34.88M | -37.40M | -27.48M | -27.00M | -32.19M | -25.23M | -23.96M | -62.38M | -34.75M | -24.11M | 14.41M | 14.28M | -11.01M | -13.06M | -11.15M | -8.45M | -6.98M | -4.03M | -1.05M | -1.97M |
| Operating Income Ratio | -400.36% | -270.44% | -164.85% | -166.05% | -1,793.98% | 36.61% | -2,499.89% | -3,235.57% | -6,400.73% | -339,954.55% | -444.96% | -80.21% | -89.30% | -91.07% | -37.89% | -162.13% | -82.61% | -58.24% | 5.83% | 7.36% | -8.58% | -20.32% | -40.56% | -150.71% | -164.25% | -144.19% | -23.44% | -96.43% |
| Total Other Income/Expenses | 1.48M | -26.64M | 194.00K | 1.34M | 3.31M | -203.00K | 2.80M | 4.52M | -15.34M | 20.32M | 236.00K | 6.59M | 6.23M | 2.01M | -766.00K | 3.74M | 756.00K | 2.28M | -8.45M | -6.43M | -3.29M | 1.51M | 1.83M | 7.62M | 3.39M | 1.49M | 1.26M | 2.12M |
| Income Before Tax | -16.86M | -22.73M | -8.48M | -4.72M | -6.23M | 9.64M | -20.28M | -24.96M | -50.23M | -17.08M | -27.24M | -20.41M | -25.96M | -23.22M | -24.72M | -58.64M | -34.00M | -21.83M | 5.97M | 7.85M | -14.30M | -11.55M | -9.32M | 662.10K | -2.72M | -2.53M | 69.88K | 145.94K |
| Income Before Tax Ratio | -367.99% | -402.96% | -161.16% | -129.33% | -1,171.05% | 35.86% | -2,196.64% | -2,739.74% | -9,216.15% | -155,236.36% | -441.13% | -60.63% | -72.01% | -83.81% | -39.10% | -152.40% | -80.82% | -52.74% | 2.41% | 4.05% | -11.14% | -17.97% | -33.91% | 11.81% | -63.98% | -90.70% | 1.56% | 7.14% |
| Income Tax Expense | 3.00 | 14.94M | -109.00K | 395.00K | -188.00K | 5.45M | -3.48M | -4.52M | -85.00K | 111.00K | -34.06M | -27.00M | 1.10M | 26.00K | 5.00K | 1.18M | -1.96M | -29.13M | 7.33M | 6.89M | 4.57M | 2.81M | -2.98M | -662.10K | 2.72M | 2.53M | -69.88K | 72.97K |
| Net Income | -16.86M | -37.67M | -8.37M | -5.12M | -6.04M | 4.19M | -16.80M | -24.96M | -50.14M | -16.56M | 6.82M | -20.41M | -27.07M | -23.22M | -24.72M | -59.82M | -32.30M | 33.39M | 10.57M | -4.79M | -21.71M | -16.38M | -2.18M | 662.10K | -2.72M | -2.53M | 69.88K | 72.97K |
| Net Income Ratio | -367.99% | -667.89% | -159.09% | -140.14% | -1,135.71% | 15.58% | -1,819.72% | -2,739.74% | -9,200.55% | -150,581.82% | 110.36% | -60.63% | -75.08% | -83.81% | -39.10% | -155.46% | -76.77% | 80.67% | 4.27% | -2.47% | -16.91% | -25.48% | -7.92% | 11.81% | -63.98% | -90.70% | 1.56% | 3.57% |
| EPS | -3.47 | -7.76 | -1.82 | -3.11 | -8.63 | 6.37 | -28.07 | -60.29 | -453.60 | -701.63 | 600.00 | -2.58K | -4.30K | -4.60K | -6.52K | -16.87K | -9.11K | 9.60K | 3.45K | -1.58K | -7.57K | -6.37K | -1.06K | -3.30K | -1.59K | -1.56K | 0.00 | 0.00 |
| EPS Diluted | -3.47 | -7.76 | -1.82 | -3.11 | -8.63 | 6.14 | -28.07 | -58.51 | -366.08 | -701.60 | 600.00 | -2.58K | -4.30K | -4.60K | -6.52K | -16.87K | -9.11K | 9.30K | 3.45K | -1.56K | -7.57K | -6.37K | -1.03K | -3.30K | -1.59K | -1.36K | 0.00 | 0.00 |
| Weighted Avg Shares Out | 4.86M | 4.86M | 4.60M | 1.64M | 699.78K | 657.63K | 598.35K | 413.96K | 110.54K | 23.61K | 11.79K | 7.91K | 6.30K | 5.04K | 3.79K | 3.55K | 3.55K | 3.47K | 3.08K | 3.04K | 2.87K | 2.57K | 2.06K | 1.97K | 1.71K | 1.63K | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 4.86M | 4.86M | 4.60M | 1.64M | 699.78K | 681.39K | 598.35K | 426.61K | 136.97K | 23.61K | 11.79K | 7.92K | 6.30K | 5.04K | 3.79K | 3.55K | 3.55K | 3.50K | 3.08K | 3.07K | 2.87K | 2.57K | 2.11K | 1.97K | 1.71K | 1.86K | 0.00 | 0.00 |
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
Aeterna Zentaris (AEZS) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $0.84 per share a year ago.
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
TORONTO and EDMONTON, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger...
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
TORONTO and EDMONTON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, are pleased to announce today that leading independent proxy...
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") today announced that it has issued a Letter to Shareholders and Management Proxy Circular ahead of its special meeting of shareholders to approve its merger...
AEZS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aeterna Zentaris Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Aeterna Zentaris Inc. (NASDAQ: AEZS) and Ceapro Inc. is fair to Aeterna shareholders. Halper Sadeh encourages Aeterna shareholders to click here to learn more...
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company
TORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, today announced that they have entered into a definitive agreement...
Aeterna Zentaris (AEZS) Reports Q2 Loss, Tops Revenue Estimates
Aeterna Zentaris (AEZS) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $0.87 per share a year ago.
Aeterna Zentaris Reports Second Quarter 2023 Financial Results
TORONTO, ONTARIO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating...
Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update
TORONTO, ONTARIO, July 13, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today provided an update on its...
Source: https://incomestatements.info
Category: Stock Reports